If you liked this article you might like

Biogen Spine Disease Drug Sales Strong in First Quarter Since Commercial Launch
Stock Futures See More Gains on a Stream of Positive Earnings
5 Things You Must Know Before the Market Opens Tuesday
Biogen Hopes New Spine Drug Data Convinces Insurers to Loosen Patient Access, Boost Sales